# Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

> **NCT05457257** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 43 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** olaparib
- **DRUG:** enzalutamide
- **DRUG:** abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05457257
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-29
- **Primary completion:** 2024-10-22
- **Final completion:** 2026-12-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457257, "Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05457257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*